Treatment Outcome of Uveitis in Autoimmune Diseases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03886233|
Recruitment Status : Unknown
Verified March 2019 by Elham youssif Ahmed Ali, Assiut University.
Recruitment status was: Not yet recruiting
First Posted : March 22, 2019
Last Update Posted : March 22, 2019
|Condition or disease||Intervention/treatment|
|Autoimmune Uveitis||Drug: Corticosteroid Series|
|Study Type :||Observational|
|Estimated Enrollment :||1 participants|
|Official Title:||Treatment Outcome of Uveitis in Autoimmune Diseases|
|Estimated Study Start Date :||March 2019|
|Estimated Primary Completion Date :||February 2021|
|Estimated Study Completion Date :||February 2021|
Traditional Treatment for Autoimmune uveitis
Corticosteroids are considered the gold standard in management of acute AU. They can only be administered after excluding infectious origin. Their use for prolonged time and/ or in high doses may be associated with serious adverse events . Therefore, it is necessary to combine them with other immunosuppressive drugs.Based on their mechanism of action, immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus).Dosage form, dosage, frequency and duration differ according to age and case severity.
Drug: Corticosteroid Series
immunosuppressives are divided into alkylating agents (cyclophosphamide and chlorambucil), antimetabolites (methotrexate, azathioprine, and Mycophenolate Mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus and sirolimus) Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab).
Biological Treatment for Autoimmune uveitis
Biological anti-inflammatory agents (for exapmle antagonists of tumor necrosis factor alpha like Infliximab and adalimumab) are also showing very promising results. In many cases, these agents will be seen listed as first choice in some autoimmune diseases, depending on the patient's history, age, sex, type and severity of the inflammatory disease.
- determination the best method for treatment of autoimmune uveitis [ Time Frame: 2 years ]compare the rates of treatment failure in the management of autoimmune uveitis between patients who received steroids, immunosuppressive drugs or biological therapies.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03886233
|Contact: Elham Y Ahmed, Bacheloremail@example.com|
|Study Chair:||Hasan L Fahmy, Prof.||Assiut University|
|Study Director:||Mohamed G Saleh, lecturer||Assiut University|